GPC3
Glypican-3
As of the edition of 20 October 2026, GPC3 (glypican-3, UniProt P51654) has 6 drugs tested at it and 6 companies on the list, 1 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P51654
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- At a membrane
- Solved structures
- 4
- Disease areas
- Cancer; Digestive system; Lungs and airways
- Registered trials of its drugs
- 9
Drugs at this target
| Status | Count |
|---|---|
| Active | 4 |
| Went quiet | 1 |
| Stopped | 1 |
| Total | 6 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Codrituzumab | Went quiet | Phase 2 | none listed |
| BAY 3547926 | Active | Phase 1 | none listed |
| MT-303 | Active | Phase 1 | none listed |
| RYZ801 | Active | Phase 2 | none listed |
| SAR444200 | Stopped | Phase 2 | none listed |
| ZW251 | Active | Phase 1 | none listed |
6 of 6 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Engaged | 4 |
| Undetermined | 1 |
| Total on the list | 6 |
| Company | Route |
|---|---|
| Sanofi | Route A |
The other 5 companies at GPC3
In the product6 companies in all; 5 are not named here, and no score is.
See the 6 companies at GPC3, ranked, with the facts behind eachRequest access. Nothing is shown until you do.